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a  b  s  t  r  a  c  t
The study aimed to evaluate the anti-Sporothrix sp. activity of the essential oil of Origanum
majorana Linn. (marjoram), its chemical analysis, and its cytotoxic activity. A total of 18
fungal isolates of Sporothrix brasiliensis (n: 17) from humans, dogs and cats, and a standard
strain of Sporothrix schenckii (n: 1) were tested using the broth microdilution technique (Clin-
ical  and Laboratory Standard Institute – CLSI M27-A3) and the results were expressed in
minimal inhibitory concentration (MIC) and minimal fungicidal concentration (MFC). The
MIC50 and MIC90 of itraconazole against S. brasiliensis were 2 g/mL and 8 g/mL, respectively,
and  the MFC50 and MFC90 were 2 g/mL and >16 g/mL, respectively, with three S. brasilien-
sis  isolates resistant to antifungal. S. schenckii was sensitive at MIC of 1 g/mL and MFC of
8  g/mL. For the oil of O. majorana L., all isolates were susceptible to MIC of ≤2.25–9 mg/mL
and MFC of ≤2.25–18 mg/mL. The MIC50 and MIC90 were ≤2.25 mg/mL and 4.5 mg/mL, respec-
tively, and the MFC50/90 values were twice more than the MIC. Twenty-two compounds were
identiﬁed by gas chromatography with a ﬂame ionization detector (CG-FID) and 1,8-cineole
and 4-terpineol were the majority. Through the colorimetric (MTT) assay, the toxicity was
observed in 70–80% of VERO cells between 0.078 and 5 mg/mL. For the ﬁrst time, the study
demonstrated the satisfactory in vitro anti-Sporothrix sp. activity of marjoram oil and further
studies are needed to ensure its safe and effective use.
©  2016 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is
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ntroduction
porotrichosis is a zoonotic mycosis caused by the fun-
us of Sporothrix schenckii complex, such as S. schenckii var.
chenckii, S. schenckii var. luriei, S. brasiliensis, S. globosa, S.
exicana and S. albicans.1,2 This disease has a worldwide
ccurrence, mainly in countries of America, such as Brazil,
exico, Colombia, Uruguay and Peru, and also in South Africa,
ndia, Japan.3,4 The infection is acquired through the trau-
atic inoculation by conidial and can be transmitted through
cratch and bite of sick cats.5,6 S. brasiliensis is considered the
ost virulent among the complex species and with a high
revalence in Brazil, being geographically restricted to this
ountry.7,8
Limited lesions to skin and subcutaneous tissue may arise
n the host and may have lymphatic involvement with sys-
emic clinical signs.9 The treatment of choice is performed
ith the antifungal itraconazole10–12; however, the appear-
nce of resistant strains of Sporothrix sp. has been observed
ecause of the indiscriminate use of several antifungals in
herapies.2,13,14
This problem has stimulated the search for new effective
hemical compounds, such as those in medicinal plants, but
nly approximately 30% of antimicrobial medications in the
arket are derived from natural products and the resources
or elaborate drugs from plants are poorly explored.15 In folk
edicine, marjoram (Origanum majorana Linn., synonymous of
ajorana hortensis Linn.) is used to treat asthma, indigestion,
ramps, headache, dizziness, depression, and rheumatism,
nd it has diuretic activity.16,17 This plant has a strong antiox-
dant activity attributed to its high content of ﬂavonoids and
henolic acids, which are used for food preservation.18 Essen-
ial oil of O. majorana L. has shown antimicrobial properties,
uch as antiviral, antibacterial and antifungal,18–22 among oth-
rs.
The pathogenic fungi of human and veterinary medical
nterest that were sensitive to the essential oil of O. majorana
. are Candida sp., Aspergillus sp., Trichophyton sp., Microspo-
um sp., Malassezia sp. and Trichosporon sp.21,23,24 These results
n vitro show its promising activity in fungal diseases, includ-
ng those with zoonotic potential. In sporotrichosis, no studies
ith O. majorana L. have been done, which encouraged the
evelopment of this work. This study aimed to evaluate
he in vitro efﬁcacy of O. majorana L. essential oil against
linical isolates of S. schenckii complex and to analyze its
hemical constituents and cytotoxic activity in mammalian
ells.
aterials  and  methods
lant  material
he essential oil of O. majorana Linn., originating from Egypt,
as obtained from Ferquima® Indústria e Comércio Ltda. (Vargem
rande Paulista, São Paulo, SP, Brazil), for which quality
arameters are described in an accompanying technical report
appearance, color, purity, odor, density – 20 ◦C, refraction
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Chemical  analysis
Chemical analysis was performed using high-resolution gas
chromatography with a ﬂame ionization detector (CG-FID)
by HP 7820A (Agilent®) equipped with an HP-5 column
(30 m × 0.32 mm × 0.25 mm)  at an initial temperature of 70 ◦C
with the addition of 3 ◦C/min up to 240 ◦C. The injector tem-
perature was 250 ◦C, and that of the FID detector was 260 ◦C.
The speed of the drag of hydrogen gas was 3 mL/min, and that
of the split was 1:30. The solution of essential oil was diluted
with 1% chloroform and injected into the chromatograph at a
volume of 1 L. Data were acquired through the EZChrom Elite
Compact® program (Agilent).
Cytotoxicity  assay
The cytotoxic effects of O. majorana L. were estimated
using the colorimetric MTT  [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] assay that measures the
reduction of the MTT dye to an insoluble and col-
ored formazan. The technique was executed as previously
described,25 and tested in mammalian cells of VERO type,
which were grown in RPMI-1640 (Roswell Park Memorial Insti-
tute medium, Sigma, Steinheim, Germany) supplemented
with l-glutamine, without sodium bicarbonate (pH 7.2) and
added of penicillin–streptomycin and fungizone in a humid-
iﬁed atmosphere of 5% CO2 at 37 ◦C. Trypsin was added
on to the cell monolayer and the cells were resuspended
in RPMI-1640, resulting in a suspension with approximately
2 × 105 cells/mL. Aliquots of this cells suspension were placed
in individual wells in 96-well microplate except ﬁrst well as
blank. Cells were incubated in RPMI-1640 medium supple-
mented with 10% fetal calf serum at CO2 5%, 37 ◦C by 24 h.
Subsequently, 100 L of the oil in seven successive concen-
trations on a logarithmic scale was added in the microplates.
Concentrations of 5–0.078 mg/mL  of the essential oil diluted
in RPMI-1640 were tested in triplicate for 48 h at 37 ◦C in
a humidiﬁed atmosphere of 5% CO2 and for control RPMI-
1640 only was used. Then, 50 L MTT solution (2.5 mg/mL)
was added in each well and incubated for 2 h and 30 min
at 37 ◦C and 5% CO2. After removal of MTT solution, 50 L
of dimethylsulfoxide (DMSO) was added to each well to dis-
solve the formazan crystals, and gentle shaking for 5 min.
The spectrophotometric absorbance of the samples was mea-
sured using a microplate reader at wavelength of 540 nm.  The
appearance of cells was monitored by inverted microscope
and the results were expressed as an inhibition percentage
relative to the control cells, which was considered 100%.
Fungal  isolates
For the antifungal susceptibility test, seventeen clinical iso-
lates of S. brasiliensis derived from humans (n: 3), dogs (n:
6), and cats (n: 8) with sporotrichosis were used along with
a standard strain of S. schenckii (IOC 1226) from human case
(n: 1), totaling eighteen tested isolates. The fungal isolates
were stored in mycology collection of the Centro de Diagnós-
tico e Pesquisa em Micologia Veterinária (Universidade Federal
de Pelotas – UFPEL – Pelotas, RS, Brazil) and cooled in an
average temperature of 4 ◦C. The mycology identiﬁcation of
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Table 1 – Minimal inhibitory concentration (MIC) and minimal fungicidal concentration (MFC) of the Origanum majorana
Linn. essential oil and itraconazole against Sporothrix brasiliensis and Sporothrix schenckii.
Origin of the isolates of
Sporothrix schenckii
complex
Origanum majorana L. (mg/mL) Itraconazole (g/mL)
MIC MFC MIC MFC
Range 50% 90% Range 50% 90% Range 50% 90% Range 50% 90%
Sporothrix brasiliensis
Humans (n: 3) ≤2.25–4.5 – – ≤2.25–4.5 – – ≤0.03–0.5 – – ≤0.03 to 2 – –
Dogs (n: 6) ≤2.25–4.5 ≤2.25 ≤2.25 ≤2.25–18 4.5 9 0.5–8 1 2 1 to >16 2 16
Cats (n: 8) ≤2.25–9 ≤2.25 4.5 ≤2.25–9 4.5 9 ≤0.03–16 2 16 0.25 to >16 2 >16
Overall (n: 17) ≤2.25–9 ≤2.25 4.5 ≤2.25–18 4.5 9 ≤0.03–16 2 8 ≤0.03 to >16 2 >16
Sporothrix schenckii
IOC 1226 (n: 1) ≤2.25 – – ≤2.25 – – 1 – – 8 – –
Overall (n: 18) ≤2.25–9 ≤2.25 4.5 ≤2.25–18 4.5 9 ≤0.03–16 1 16 ≤0.03 to >16 2 >16
%, M50%, MIC/MFC at which 50% of isolates were inhibited/eliminated; 90
S. brasiliensis was analyzed using the polymerase chain reac-
tion – restriction fragment length polymorphism (PCR-RFLP),
proposed by Rodrigues et al.26
Antifungal  activity
The antifungal susceptibility tests were performed using the
broth microdilution technique, according to the M27-A3 guide-
lines of the Clinical and Laboratory Standards Institute,27
adapted for the use of essential oil. Subcultures in Brain-
Heart-Infusion agar (BHI, Acumedia, Lansing, MI, USA) at 35 ◦C
for 48 h were performed. A portion of each fungal colony
was transferred to individual tubes containing sterile saline
solution and adjusted according to the scale of 1.0 McFarland
and in the ultraviolet (UV)–visible spectrophotometer (Spec-
trum Instruments Co., Shanghai, China) in transmittance at
530 nm and at an absorbance of 80–82%. The suspensions were
adjusted in saline solution (1:100) and, then, in RPMI-1640 with
3-morpholinopropane-1-sulfonic acid – MOPS – (1:20) in order
to obtain the ﬁnal inoculum concentration of 5 × 104 CFU/mL.
In a microplate with ninety-six wells containing 100 L
of RPMI-1640 with MOPS in each well, 100 L of essential oil
of O. majorana L. containing 1% Tween 80 was added to the
column corresponding to a higher concentration of the prod-
uct, and serial dilutions were performed. The oil plant was
tested in the concentrations of 72–2.25 mg/mL. Then, 100 L
of the inoculum was added to all wells except in the nega-
tive control, where 100 L of the marjoram essential oil was
added. Itraconazole was used as the positive control and
was prepared in dimethyl sulfoxide and diluted in RPMI-1640
medium with MOPS in order to obtain the ﬁnal concentra-
tions of 16–0.0313 g/mL. The microplates were incubated on
a rotatory shaker (Certomat® BS-1, B. Sartorius, Göttingen,
Germany) at 35 ◦C for 72 h, and the minimal inhibitory concen-
tration (MIC) was visually compared with that of the negative
control and was deﬁned as the lowest concentration of the
tested product inhibiting the visible growth of the fungus
(100% inhibition).
For the minimal fungicidal concentration (MFC), 10 L of
aliquots of the wells with no fungal growth was transferred toIC/MFC at which 90% of isolates were inhibited/eliminated.
Petri dishes containing Sabouraud dextrose agar (Acumedia,
Lansing, MI, USA) and incubated at 35 ◦C for 72 h to visualize
fungal growth. MFC  was determined to be the lowest concen-
tration able to eliminate fungal growth. All experiments were
performed in duplicate.
Statistical  analysis
The analysis of variance and comparison of geometric means
were performed according to Tukey test using the statistical
software BioEstat®, 5.3 version, and value p < 0.05 was consid-
ered signiﬁcant.
Results
Antifungal  activity
According to the results of the anti-Sporothrix sp. activity of
the essential oil of O. majorana L. and itraconazole (Table 1), no
signiﬁcant difference existed between the results in the MIC
values; however, the MFC values differed statistically (p = 0.05)
between itraconazole and essential oil, in which O. majorana
L. presented better results. All tested isolates were suscepti-
ble to the essential oil of marjoram with fungistatic activity
being observed at concentrations of ≤2.25–9 mg/mL, while
fungicidal activity occurred between ≤2.25 and 18 mg/mL. The
concentrations of the oil up to 9 mg/mL  showed antifungal
activity against all S. brasiliensis,  the MIC50 and MIC90 being
observed at the concentrations ≤2.25 mg/mL  and 4.5 mg/mL,
respectively. At the minimal concentration tested of the oil,
66.7% (2/3) of the humans isolates, 83.3% (5/6) of the iso-
lates from dogs and 50% (4/8) from cats were sensitive (MIC
≤2.25 mg/mL), as well as the standard strain of S. schenckii. In
the fungicidal activity, the MFC50 and MFC90 values of overall
S. brasiliensis were 4.5 mg/mL  and 9 mg/mL, respectively, and
were twice the MIC50/90 values, whereas the standard strain
was more  sensitive (MFC ≤2.25 mg/mL). In relation to the itra-
conazole, all isolates were sensitive to the fungistatic activity
between the MIC values ≤0.03 and 16 g/mL, which MIC50
was 1 g/mL and MIC90 was 16 g/mL. However, the fungicidal
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Table 2 – Chemical constituents identiﬁed in the
essential oil of Origanum majorana L. and respective
concentrations through high resolution gas
chromatography in a ﬂame ionization detector (CG-FID).
Constituents Retention
rate
Area Concentration
(%)
-Thujene 932 281,814 1.1
-Pinene 932 494,138 2.0
Camphene 941 96,074 0.4
Sabinene 946 1,669,329 6.7
-Pinene 975 470,225 1.9
Myrcene 984 408,894 1.6
-Phellandrene 1003 226,808 0.9
-Terpinene 1015 1,152,102 4.6
p-Cymene 1019 1,755,163 7.0
Limonene 1023 1,316,921 5.3
1,8-Cineole 1027 5,222,929 20.9
-Ocimene 1056 34,661 0.1
-Terpinene 1089 2,130,943 8.5
Trans sabinene hydrate 1094 564,967 2.3
Linalool 1099 1,096,294 4.4
Camphor 1142 48,346 0.2
Terpinen-4-ol 1175 5,100,062 20.4
-Terpineol 1188 1,162,894 4.7
Linalyl acetate 1261 438,735 1.8
Bornila acetate 1285 212,333 0.8
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Fig. 1 – Cytotoxic percentage (%) of the essential oil of
Origanum majorana L. in VERO cells tested through MTT-Caryophyllene 1421 546,553 2.2
Humulene 1453 41,993 0.2
Others 517,426 2.1
ctivity was observed between ≤0.03 and >16 g/mL, where
FC50 was 2 g/mL, but the MFC90 was >16 g/mL, indicat-
ng that 17.6% (3/17) of the S. brasiliensis were resistant to the
aximal concentration tested of this antifungal.
hemical  composition
hemical analysis found twenty-two compounds, and 1,8-
ineole was the majority component, followed by 4-terpineol,
-terpinene, p-cymene, sabinene, and others (Table 2).
ytotoxic  effects
n the observed values of MIC50 and MIC90 for total isolates,
he cytotoxicity of O. majorana L. occurred between 77.5% and
8.91%. The toxicity activity in mammalian cells was directly
roportional to tested concentrations and decreased to 73.45%
t a concentration of 0.078 mg/mL  (Fig. 1).
iscussion
ntifungal  activity
he drug of choice in the treatment of sporotrichosis was
ffective against several S. brasiliensis, being similar to the
ndings of Marimon et al.,2 that showed in vitro activity
etween 0.5 and 2 g/mL against twenty-three isolates of S.
rasiliensis, with MIC50 and MIC90 of 0.5 g/mL and 1 g/mL,
espectively. In our work, the MIC50 and MIC90 found were g/mL and 8 g/mL, demonstrating that the fungal isolates
f S. brasiliensis originating from humans and animals in the
outh of Brazil were twice more  resistant.assay in the concentration of 0.078–5 mg/mL.
In isolates from humans, no resistance was observed, and
according Kauffman et al.28 and Yamada et al.,29 the resis-
tance was lower compared to that of animals, mainly cats,
due to greater care during human therapy in relation to their
own health. In relation to feline sporotrichosis, it is known to
have a high incidence in the Southeast and Southern regions
of Brazil.8,11,30,31 MIC50 of itraconazole against S. brasiliensis
isolated from cats were 2 g/mL, but the MIC90 was 16 g/mL,
demonstrating its lower susceptibility to antifungal. In the
overall S. brasiliensis tested, one clinical isolate from a dog and
two isolates from cats were resistant to the fungicidal activity
(MFC >16 g/mL).
This observation may be a reﬂection of previous factors
that favor the emergence of antifungal resistance. It is noticed
that the antifungal administered in animals may not always
be the same used in humans and its efﬁcacy may be affected
due to pharmacokinetics parameters and kind of formulation,
among others,32 and a difference in the pharmaceutical tech-
nology between human and veterinary drugs may occur,33
which may inﬂuence the therapeutic antifungal response.
Besides, the irregularities in veterinary therapeutic manage-
ment by animal owners are common due to the difﬁculties in
the oral administration and high cost of antifungals and this
often culminates in the abandonment of therapy, particularly
when there is improvement of skin lesions.34
The resistance of Sporothrix spp. to itraconazole has been
evidenced by Rodrigues et al.,14 and this problem reﬂects in
an alert because sporotrichosis is important in the public
health. Interestingly, the same resistant isolates were suscep-
tible to essential oil in concentrations equal to or less than
9 mg/mL, thus suggesting that this plant can be used for fur-
ther studies in the treatment of sporotrichosis. In accordance
with our study, Souza et al.23 showed the promising activity
of the commercial essential oil of O. majorana L. at 160 L/mL
against pathogenic fungi, including in strains of Candida
albicans, C. tropicalis, Cryptococcus neoformans, T. mentagrophytes,
M. gypseum and A. ﬂavus,  which were resistant to conven-
tional antifungal, as amphotericin B, 5-ﬂuorocytosine and
ﬂuconazole. This observation reﬂects in the promising use of
this essential oil in antifungal therapies.
No valid criteria exist for the minimal antifungal concen-
trations in vitro tests with plant extracts,35 but O. majorana
L. oil showed satisfactory activity with MIC50 and MIC90
of ≤2.25 mg/mL  and 4.5 mg/mL, respectively, including in
 i c r o
r900  b r a z i l i a n j o u r n a l o f m
resistant isolates to itraconazole (n: 3), that were sensitive to
the plant at MIC  of ≤2.25 mg/mL  for one isolate from dog and
one from cat, and at MIC  of 9 mg/mL  for one isolate from cat.
No studies were found on the activity of O. majorana L. in S.
schenckii complex, and for the ﬁrst time, the in vitro sensibility
of S. brasiliensis to this plant was studied.
Similar to our study, the resistance of S. schenckii and
S. brasiliensis to itraconazole also was reported as sensitive
to plant extracts from the Pterocaulon genus35 and Camellia
sinensis L.,36 respectively, indicating the promising use of the
several plants in the sporotrichosis. Furthermore, resistance
of bacteria and yeasts to antimicrobial drugs was sensitive
to the essential oils of Rosmarinus ofﬁcinalis L.37 and Origanum
vulgare L.38,39 showing that, as found in this study with O. majo-
rana L., other medicinal plants also are potential candidates
as new antimicrobial agents. Given this fact, it is necessary to
explore the studies for their promising use in the treatment of
sporotrichosis.
Chemical  composition
The chemical compounds were similar to those scientiﬁcally
described.18,21,24,40 However, our data differed from the ﬁnd-
ings by Marino et al.,41 in which thymol and carvacrol were
prevalent. The presence of phenolic compounds in plants is
highly correlated to antimicrobial properties,40,42 but the iden-
tiﬁed compounds were predominated by terpenoids, which
were related to antimicrobial activity when tested alone.43 The
plant causes an increase in the permeability of the cytoplas-
matic fungal membrane, destroying the physical structure.44
However, Souza et al.23 suggested that the essential oil of O.
majorana L. acts as an inhibitor of the microorganism’s cell
wall, although other mechanisms for expressing their anti-
Sporothrix sp. activity may be involved.
Cytotoxic  effects
O. majorana L. oil presented a cytotoxicity between 73.45% and
78.91% in the tested concentrations, which were high, but
the gradual reduction of the cytotoxicity to the lower tested
concentration should be noted. In overall isolates, 66.67%
(12/18) of tested Sporothrix spp. were sensitive to the MIC
≤2.25 mg/mL, indicating that the lower concentrations may
present inhibitory activity with lower cytotoxicity. Although
the maximal non-toxic concentration of O. majorana L. essen-
tial oil in VERO cells was 3.2 g/mL,22 this value was four
times lower than the minimal tested concentration. However,
it is noticed that the use of the O. majorana L. oil against
sporotrichosis need to be studied at its effective antifungal
concentrations and, also, our study was performed in vitro.
According to Nogueira and Andrade,45 the mammalian
cells in the MTT  test are more  susceptible in comparison to
the in vivo test due to the direct exposure of the product,
whereas to the in vivo the product is inﬂuenced by the route of
administration under consideration, that can suffer inter-
nal actions by oral administration, as well as inﬂuence by
topical absorption, and may present lower toxic potential.
The dose and frequency of administration can inﬂuence the
degree of toxicity of medicinal plants,46 and low doses can
cause an allergic reaction in sensitive patients as well as skin b i o l o g y 4 7 (2 0 1 6) 896–901
irritations.47,48 Studies on the toxic effects of this plant in vivo
should be conducted in order to evaluate the inﬂuence of its
dose and the route of administration in patients with sporotri-
chosis.
Conclusion
The in vitro activity of O. majorana L. essential oil against S.
brasiliensis and S. schenckii, including in resistant isolates to
itraconazole, encourages greater studies on antifungal poten-
tial of this promising plant, that had 1,8-cineole as majority
compound among chemical constituents identiﬁed. However,
the cytotoxic activity of O. majorana L. oil was observed
between 70% and 80% of mammalian cells in all concentra-
tions tested. Further studies are needed to ensure its safe and
effective use.
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